PMID- 36017310
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20220829
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - Prevalence and risk factors of vascular complications in type 2 diabetes 
      mellitus: Results from discover Middle East and Africa cohort.
PG  - 940309
LID - 10.3389/fendo.2022.940309 [doi]
LID - 940309
AB  - BACKGROUND: We evaluated the prevalence of vascular complications and associated 
      risk factors in individuals with type 2 diabetes mellitus (T2DM) initiating 
      second-line glucose-lowering therapy from the Middle East and Africa (MEA) cohort 
      of the 3-year prospective DISCOVER study involving 15,992 patients in 38 
      countries. METHODS: Baseline cross-sectional data collected from healthcare 
      settings were used to assess micro and macrovascular complications prevalence as 
      crude and age- and sex-standardised. The multi-variable analysis assessed factors 
      associated with these complications. RESULTS: Of 3,525 enrolled patients (mean 
      age: 54.3 +/- 10.8 years), >40% had hypertension and hyperlipidaemia. Metformin 
      monotherapy was the first-line therapy in 56.5%, followed by 
      metformin+sulphonylurea (20.3%). Crude and standardised prevalence of 
      microvascular complications were 17.7% and 16.9% (95% confidence interval [CI], 
      16.77-16.98) and macrovascular complications were 10.7% and 8.7% (95% CI, 
      8.59-8.76). Factors significantly (p<0.05) associated with micro and 
      macrovascular complications (odds ratios [95% CI]) were age (1.24 [1.12-1.39] and 
      1.58 [1.35-1.84]), male sex (1.33 [1.04-1.70] and 1.71 [1.22-2.40]), 
      hyperlipidaemia (1.33 [1.07-1.65] and 1.96 [1.46-2.63]) and hypertension (1.75 
      [1.40-2.19] and 2.84 [2.07-3.92]). CONCLUSION: A substantial burden of vascular 
      complications with prominent risk factors in the MEA cohort calls for early 
      preventive interventions.
CI  - Copyright (c) 2022 Hafidh, Malek, Al-Rubeaan, Kok, Bayram, Echtay, Rajadhyaksha and 
      Hadaoui.
FAU - Hafidh, Khadija
AU  - Hafidh K
AD  - Diabetes Unit, Rashid Hospital, Dubai, United Arab Emirates.
FAU - Malek, Rachid
AU  - Malek R
AD  - Internal Medicine, Setif University Hospital, Setif, Algeria.
FAU - Al-Rubeaan, Khalid
AU  - Al-Rubeaan K
AD  - Research and Scientific Centre, Sultan Bin Abdulaziz Humanitarian City, Riyadh, 
      Saudi Arabia.
FAU - Kok, Adri
AU  - Kok A
AD  - University of the Witwatersrand, Netcare Union and Clinton Hospitals, Alberton, 
      South Africa.
FAU - Bayram, Fahri
AU  - Bayram F
AD  - Endocrinology and Metabolism, Erciyes University Faculty of Medicine, Kayseri, 
      Turkey.
FAU - Echtay, Akram
AU  - Echtay A
AD  - Endocrinology Division, Rafik Hariri University Hospital, Beirut, Lebanon.
FAU - Rajadhyaksha, Viraj
AU  - Rajadhyaksha V
AD  - Medical Affairs Department, AstraZeneca Middle East and Africa, Luton, United 
      Kingdom.
FAU - Hadaoui, Ahmed
AU  - Hadaoui A
AD  - Medical Affairs Department, AstraZeneca Algeria, Algiers, Algeria.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220809
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Cardiovascular Diseases/complications
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/epidemiology/prevention & control
MH  - Humans
MH  - *Hypertension/complications/epidemiology
MH  - Male
MH  - *Metformin
MH  - Middle Aged
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
PMC - PMC9396276
OTO - NOTNLM
OT  - Middle East and Africa
OT  - macrovascular complication
OT  - microvascular complications
OT  - risk factors
OT  - type 2 diabetes
OT  - vascular complication
COIS- KH has received speaker fees and research support from AstraZeneca, Boehringer 
      Ingelheim, Servier, Sanofi, Merck & Co., Novartis, Novo Nordisk, Pfizer, and Eli 
      Lilly. RM has received honoraria as a speaker and a board member from Novo 
      Nordisk, Sanofi, Eli Lilly, AstraZeneca, Merck, Novartis and Hikma. FB reports 
      speaker honoraria and travel sponsorship from Bilim Ilac, Abbott, Novo Nordisk, 
      Sanofi Genzyme, Pfizer, and Eczacibasi Ilac, and advisory board and consultancy 
      fees from Novo Nordisk, Sanofi Genzyme, Abbott, Pfizer, and Bilim Ilac. AE has 
      received advisory board fees from AstraZeneca, Boehringer Ingelheim, Merck, and 
      Novo Nordisk, and speaker fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, 
      Merck, Novartis, Novo Nordisk, and Sanofi. AK has received speaker and advisory 
      board fees from Novo Nordisk, AstraZeneca, Merck & Co., Eli Lilly, Aspen Pharma, 
      Sanofi, Boehringer Ingelheim, Cipla, Mylan, Pharmadynamics, Adcock Ingram, and 
      Pfizer. AH and VR are employees of AstraZeneca. The remaining author declares 
      that the research was conducted in the absence of any commercial or financial 
      relationships that could be construed as a potential conflict of interest. This 
      study received funding from AstraZeneca. AstraZeneca as funder had the following 
      involvement with the study: study design, study management as per ICH GCP Sponsor 
      responsibilities guidelines, decision to publish and the preparation of the 
      manuscript. The data collection was performed by local CROs contracted by 
      AstraZeneca and Data analysis was carried out by an independent academic centre 
      (Mid America Heart Institute).
EDAT- 2022/08/27 06:00
MHDA- 2022/08/30 06:00
PMCR- 2022/01/01
CRDT- 2022/08/26 02:30
PHST- 2022/05/10 00:00 [received]
PHST- 2022/07/20 00:00 [accepted]
PHST- 2022/08/26 02:30 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.940309 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Aug 9;13:940309. doi: 
      10.3389/fendo.2022.940309. eCollection 2022.